RxDoctor Payments DataLook up a doctor →

Willis Holloway, MD

Psychiatry · Oklahoma City, OKNPI 1023054434

Payments from drug & device makers

$1,393,214in general payments, 2019–2025

Across 528 payments — averaging $2638.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka Pharmaceutical Development & Commercialization, Inc.$336K
  • Genentech, Inc.$234K
  • AbbVie$164K
  • F. Hoffmann-la Roche AG$160K
  • Janssen Research & Development, LLC$152K
  • Sunovion Pharmaceuticals Inc.$62K
  • plus $284K from 22 others

What the payments were for

  • Consulting fees$7201%
  • Speaking & faculty fees$80,71888%
  • Travel & lodging$5,7256%
  • Food & beverage$4,4285%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,393,214 in reported general payments places this provider in the 95th percentile of 328 psychiatry providers in Oklahoma.

See all psychiatry providers in Oklahoma

Medicare billing

Part B allowed, 2024
$5,747
Medicare patients
81
Services billed
135

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyvanseLisdexamfetamine Dimesylate56$21,420
Lisdexamfetamine Dimesylate55$11,130
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine267$7,647
Clozapine122$7,579
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl55$4,509
Naltrexone Hcl22$2,144
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine46$1,743
Methylphenidate Hcl38$1,414
Quetiapine Fumarate42$943
Clonazepam87$608
Carbamazepine ErCarbamazepine12$584
Lurasidone Hcl16$574
Lorazepam50$543
Hydroxyzine Pamoate24$444
Duloxetine Hcl12$410

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$16,419$21,42056 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 328 psychiatry providers in Oklahoma.

Other psychiatry in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →